BOSTON?(BUSINESS WIRE)?
Analysis Group, a leading provider of economic, financial, and strategy
consulting, and health care outcomes research and services, welcomes new
academic affiliate Professor Gordon Liu to the firm.
Dr. Liu is a professor of economics and the director of China Center for
Health Economics Research at Peking University?s Guanghua School of
Management. He is a leading expert on health and development
economics, health policy reform, and pharmaceutical economics in China,
and a key figure in Chinese health care reform efforts.
?We are delighted to welcome Dr. Liu to our distinguished group of
health care experts,? said Analysis Group President and CEO Martha S.
Samuelson. ?He brings a deep knowledge of international health care
policy and economics to our practice ? a perspective that is critical as
we respond to clients? growing needs for high-quality analyses in China.?
Dr. Liu has undertaken several research projects funded by the State
Council Health Reform Office, the National Science Foundation, UNICEF,
the World Bank, and the China Medical Board. He serves on the State
Council Health Reform Advisory Commission and is president of the
Chinese Society for Pharmacoeconomics and Outcomes Research. He
previously served as president of the Chinese Economists Society and was
the founding chair of the Asian Consortium for the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR). ?My colleagues and
I look forward to collaborating with Dr. Liu,? said Managing Principal
Eric Q. Wu. ?His multifaceted understanding of China?s health care
reform efforts and the country?s pharmaceuticals market will complement
and strengthen Analysis Group?s research capabilities and further our
goal of providing high-quality consulting services globally.?
?The quality and rigor that Analysis Group teams apply to health
outcomes research hold great appeal for those of us in the academic and
scientific communities in China,? said Dr. Liu. ?By affiliating with
Analysis Group, we can play a central role in business planning and
policy discussions as stakeholders across China and the global health
care industry seek balance between the efficacy of treatments and the
pressures of cost containment.?
Dr. Liu is a coeditor of Value in Health, the journal of ISPOR,
and the editor in chief of the China Journal of Pharmaceutical
Economics. Additionally, he is on the editorial boards of the Global
Handbook of Health Economics, Chinese Journal of Health Economics, and
the European Health Economic Review. Prior to joining Peking
University, Dr. Liu was a tenured associate professor at the University
of North Carolina at Chapel Hill and an assistant professor at the
University of Southern California.
He earned a Ph.D. in economics from The Graduate Center at City
University of New York; an M.S. in statistics from Southwestern
University of Finance and Economics; and a B.S. in mathematics from
Southwest University for Nationalities.
With more than 550 professionals with advanced degrees and expertise in
health outcomes research, epidemiology, strategy, biostatistics,
economics, and other quantitative disciplines, Analysis Group (www.analysisgroup.com)
has established a leadership role in the science, economics, and
business strategy of the global health care industry.
tupac hologram pulitzer prize winners nfl 2012 schedule gmail down tim lincecum ryan oneal
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.